CY1113247T1 - Νουκλεϊνικα οξεα με τιτλο 273ρ4β7 και η χρηση τους στην ανιχνευση καρκινου - Google Patents

Νουκλεϊνικα οξεα με τιτλο 273ρ4β7 και η χρηση τους στην ανιχνευση καρκινου

Info

Publication number
CY1113247T1
CY1113247T1 CY20121100966T CY121100966T CY1113247T1 CY 1113247 T1 CY1113247 T1 CY 1113247T1 CY 20121100966 T CY20121100966 T CY 20121100966T CY 121100966 T CY121100966 T CY 121100966T CY 1113247 T1 CY1113247 T1 CY 1113247T1
Authority
CY
Cyprus
Prior art keywords
title
variants
fragment
gene
cancer test
Prior art date
Application number
CY20121100966T
Other languages
English (en)
Inventor
Pia M Challita-Eid
Mary Faris
Arthur B Raitano
Aya Jakobovits
Wangmao Ge
Original Assignee
Agensys, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agensys, Inc. filed Critical Agensys, Inc.
Publication of CY1113247T1 publication Critical patent/CY1113247T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

Περιγράφονται ένα νέο γονίδιο 273Ρ4Β7 και η κωδικοποιημένη πρωτεΐνη του, και παραλλαγές αυτών, όπου το 273Ρ4Β7 επιδεικνύει ιστοειδική έκφραση σε κανονικό ιστό ενήλικα, και εκφράζεται κατά παρεκτροπή στους καρκίνους που καταγράφονται στον Πίνακα I. Συνεπώς, το 273Ρ4Β7 παρέχει διαγνωστικό, προγνωστικό, προφυλακτικό ή/και θεραπευτικό στόχο για τον καρκίνο. Το γονίδιο 273Ρ4Β7 ή κλάσμα αυτού, ή η κωδικοποιημένη πρωτεΐνη του, ή παραλλαγές αυτών, ή κλάσμα αυτών, μπορούν να χρησιμοποιηθούν για να προκληθεί μια χυμική ή κυτταρική ανοσοαπόκριση, ενώ αντισώματα ή Τ κύτταρα αντιδρώντα με το 273Ρ4Β7 μπορούν να χρησιμοποιηθούν στην ενεργητική ή παθητική ανοσοποίηση.
CY20121100966T 2002-08-16 2012-10-17 Νουκλεϊνικα οξεα με τιτλο 273ρ4β7 και η χρηση τους στην ανιχνευση καρκινου CY1113247T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US40430602P 2002-08-16 2002-08-16
US42329002P 2002-11-01 2002-11-01
EP03788558A EP1576132B1 (en) 2002-08-16 2003-08-15 Nucleic acids entitled 273p4b7 and their use in detection of cancer

Publications (1)

Publication Number Publication Date
CY1113247T1 true CY1113247T1 (el) 2016-04-13

Family

ID=31891426

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20121100966T CY1113247T1 (el) 2002-08-16 2012-10-17 Νουκλεϊνικα οξεα με τιτλο 273ρ4β7 και η χρηση τους στην ανιχνευση καρκινου

Country Status (12)

Country Link
US (16) US20040081653A1 (el)
EP (6) EP1576170B1 (el)
JP (6) JP2006513724A (el)
AU (6) AU2003243151A1 (el)
CA (5) CA3066279A1 (el)
CY (1) CY1113247T1 (el)
DK (2) DK1576170T3 (el)
ES (2) ES2392341T3 (el)
IL (6) IL166532A (el)
PT (2) PT1576170E (el)
SI (2) SI1576170T1 (el)
WO (5) WO2004016733A2 (el)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7271240B2 (en) * 2001-03-14 2007-09-18 Agensys, Inc. 125P5C8: a tissue specific protein highly expressed in various cancers
AU2003258127A1 (en) * 2002-08-06 2004-02-23 Diadexus, Inc. Compositions and methods relating to ovarian specific genes and proteins
WO2004016733A2 (en) 2002-08-16 2004-02-26 Agensys, Inc. Nucleic acid and corresponding protein entitled 251p5g2 useful in treatment and detection of cancer
US8632994B2 (en) * 2003-12-01 2014-01-21 Dako Denmark A/S Methods and compositions for immuno-histochemical detection
US20060019396A1 (en) * 2004-06-07 2006-01-26 Tissuegene, Inc. Retroviral vectors with enhanced efficiency of transgene expression and safety
ES2527961T3 (es) * 2005-09-26 2015-02-02 Medarex, L.L.C. Anticuerpos monoclonales humanos para CD70
TW200745163A (en) 2006-02-17 2007-12-16 Syntonix Pharmaceuticals Inc Peptides that block the binding of IgG to FcRn
IN2009KN02404A (el) * 2006-12-14 2015-08-07 Medarex Inc
EP2769731A1 (en) * 2007-02-23 2014-08-27 The Trustees of Columbia University in the City of New York Methods to activate or block the HLA-E/QA-1 restricted CD8+ T cell regulatory pathway to treat immunological disease
KR20100040951A (ko) 2007-08-09 2010-04-21 신토닉스 파마수티칼스, 인코포레이티드 면역조절성 펩티드
US8722860B2 (en) * 2009-04-16 2014-05-13 Abbvie Biotherapeutics Inc. Anti-TNF-α antibodies and their uses
WO2011028257A1 (en) * 2009-08-24 2011-03-10 The Trustees Of Columbia University In The City Of New York Assay for determining health of cd8+ t cells
WO2011112599A2 (en) * 2010-03-12 2011-09-15 The United States Of America, As Represented By The Secretary. Department Of Health & Human Services Immunogenic pote peptides and methods of use
US8449512B2 (en) 2010-04-09 2013-05-28 Davinci Biomedical Research Products Inc. Stoma stabilitating device and method
TW202344270A (zh) 2010-09-29 2023-11-16 美商艾澤西公司 與191p4d12蛋白結合之抗體藥物共軛物(adc)
AU2012254169B2 (en) * 2011-02-25 2016-02-25 Wellstat Diagnostics, Llc Assays for detecting enzymatic activity
WO2012164004A1 (en) 2011-06-01 2012-12-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Novel antigen peptide and uses thereof
WO2013055929A1 (en) 2011-10-12 2013-04-18 The General Hospital Corporation Non-n-glycosylated recombinant human annexin a2
EA031025B1 (ru) 2012-12-21 2018-11-30 Сиэтл Дженетикс, Инк. Антитела против ntb-a и связанные с ними композиции и способы
WO2014138188A1 (en) 2013-03-07 2014-09-12 The General Hospital Corporation Human ctla4 mutants and use thereof
US20160340659A1 (en) * 2014-01-30 2016-11-24 Yissum Research And Development Company Of The Hebrew University Of Jerusalem Ltd. Actin binding peptides and compositions comprising same for inhibiting angiogenesis and treating medical conditions associated with same
KR101503341B1 (ko) * 2014-03-12 2015-03-18 국립암센터 자가암항원 특이적 cd8+ t 세포의 분리 및 증식방법
US9616114B1 (en) 2014-09-18 2017-04-11 David Gordon Bermudes Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
US11596652B2 (en) 2015-02-18 2023-03-07 Enlivex Therapeutics R&D Ltd Early apoptotic cells for use in treating sepsis
US11497767B2 (en) 2015-02-18 2022-11-15 Enlivex Therapeutics R&D Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11304976B2 (en) 2015-02-18 2022-04-19 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11000548B2 (en) 2015-02-18 2021-05-11 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11318163B2 (en) 2015-02-18 2022-05-03 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
IL303543A (en) 2015-02-18 2023-08-01 Enlivex Therapeutics Rdo Ltd Combined immunotherapy and cytokine control therapy for cancer treatment
US10857181B2 (en) 2015-04-21 2020-12-08 Enlivex Therapeutics Ltd Therapeutic pooled blood apoptotic cell preparations and uses thereof
JP6884155B2 (ja) 2016-02-18 2021-06-09 エンリヴェックス セラピューティクス リミテッド 癌治療のための併用免疫療法及びサイトカイン制御療法
WO2018035046A1 (en) 2016-08-15 2018-02-22 President And Fellows Of Harvard College Treating infections using idsd from proteus mirabilis
US10350280B2 (en) * 2016-08-31 2019-07-16 Medgenome Inc. Methods to analyze genetic alterations in cancer to identify therapeutic peptide vaccines and kits therefore
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
BR112019007714B1 (pt) 2017-01-06 2022-01-18 Eutilex Co., Ltd Anticorpos anti-4-1bb, uso do mesmo, composição farmacêutica, métodos para determinar uma dose, para aumentar a secreção de ifn-gama por uma célula in vitro e para proliferação ex vivo ou isolamento de células t ativadas e uso das mesmas
JP7106810B2 (ja) * 2018-04-19 2022-07-27 学校法人 埼玉医科大学 新規肺がんマーカー
CN108875628A (zh) * 2018-06-14 2018-11-23 攀枝花学院 行人检测方法
EP3931335A2 (en) 2019-02-25 2022-01-05 Novartis AG Compositions and methods to treat bietti crystalline dystrophy
BR112021016501A2 (pt) 2019-02-25 2021-10-26 Novartis Ag Composições e métodos para tratar distrofia cristalina de bietti
CN110147939B (zh) * 2019-04-24 2022-04-08 中国食品药品检定研究院 一种仿制药品的工艺评价方法和系统
WO2022051591A2 (en) 2020-09-04 2022-03-10 Novarock Biotherapeutics, Ltd. Nectin-4 antibodies and uses thereof
AU2022328339A1 (en) * 2021-08-13 2024-01-04 Agensys, Inc. Methods for treating non-muscle invasive bladder cancer (nmibc) with antibody drug conjugates (adc) that bind to 191p4d12 proteins

Family Cites Families (252)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL6903384A (el) 1969-03-05 1970-09-08
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US4870009A (en) 1982-11-22 1989-09-26 The Salk Institute For Biological Studies Method of obtaining gene product through the generation of transgenic animals
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4736866A (en) 1984-06-22 1988-04-12 President And Fellows Of Harvard College Transgenic non-human mammals
US5430136A (en) 1984-10-16 1995-07-04 Chiron Corporation Oligonucleotides having selectably cleavable and/or abasic sites
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US5506337A (en) 1985-03-15 1996-04-09 Antivirals Inc. Morpholino-subunit combinatorial library and method
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5359100A (en) 1987-10-15 1994-10-25 Chiron Corporation Bifunctional blocked phosphoramidites useful in making nucleic acid mutimers
US5124246A (en) 1987-10-15 1992-06-23 Chiron Corporation Nucleic acid multimers and amplified nucleic acid hybridization assays using same
GB8724885D0 (en) 1987-10-23 1987-11-25 Binns M M Fowlpox virus promotors
US5254678A (en) 1987-12-15 1993-10-19 Gene Shears Pty. Limited Ribozymes
JP3040121B2 (ja) * 1988-01-12 2000-05-08 ジェネンテク，インコーポレイテッド 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
US5785973A (en) * 1988-02-01 1998-07-28 Praxis Biologics, Inc. Synthetic peptides representing a T-cell epitope as a carrier molecule for conjugate vaccines
US5010175A (en) 1988-05-02 1991-04-23 The Regents Of The University Of California General method for producing and selecting peptides with specific properties
CA1340323C (en) 1988-09-20 1999-01-19 Arnold E. Hampel Rna catalyst for cleaving specific rna sequences
US5539084A (en) * 1989-02-17 1996-07-23 Coselco Mimotopes Pty. Ltd. Method for the use and synthesis of peptides
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
ATE104857T1 (de) 1989-03-07 1994-05-15 Genentech Inc Kovalente konjugate von lipiden und oligonukleotiden.
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
WO1991004753A1 (en) 1989-10-02 1991-04-18 Cetus Corporation Conjugates of antisense oligonucleotides and therapeutic uses thereof
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
ATE157012T1 (de) 1989-11-03 1997-09-15 Univ Vanderbilt Verfahren zur in vivo-verabreichung von funktionsfähigen fremden genen
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
ATE356869T1 (de) 1990-01-12 2007-04-15 Amgen Fremont Inc Bildung von xenogenen antikörpern
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5279833A (en) 1990-04-04 1994-01-18 Yale University Liposomal transfection of nucleic acids into animal cells
US5204253A (en) 1990-05-29 1993-04-20 E. I. Du Pont De Nemours And Company Method and apparatus for introducing biological substances into living cells
IE66205B1 (en) 1990-06-14 1995-12-13 Paul A Bartlett Polypeptide analogs
US5723286A (en) 1990-06-20 1998-03-03 Affymax Technologies N.V. Peptide library and screening systems
JP3179481B2 (ja) 1990-06-27 2001-06-25 プリンストン ユニバーシティ 突然変異体ｐ５３検出用プローブ
US5650489A (en) 1990-07-02 1997-07-22 The Arizona Board Of Regents Random bio-oligomer library, a method of synthesis thereof, and a method of use thereof
SE9002480D0 (sv) 1990-07-23 1990-07-23 Hans Lilja Assay of free and complexed prostate-specific antigen
US5733731A (en) 1991-10-16 1998-03-31 Affymax Technologies N.V. Peptide library and screening method
AU3665893A (en) 1992-02-12 1993-09-03 United States Of America, As Represented By The Secretary, Department Of Health And Human Services, The Sequences characteristic of human gene transcription product
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
US5541061A (en) 1992-04-29 1996-07-30 Affymax Technologies N.V. Methods for screening factorial chemical libraries
JP3285355B2 (ja) 1992-06-04 2002-05-27 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア ｉｎｖｉｖｏ遺伝子治療のための方法及び組成物
JP3782100B2 (ja) 1992-08-07 2006-06-07 エピミューン，インコーポレイティド Ｈｌａ結合性ペプチド及びその用途
JP3472587B2 (ja) * 1992-08-28 2003-12-02 アベンティス ファーマ株式会社 骨関連カルボキシペプチダーゼ様タンパク質およびその製造法
US5288514A (en) 1992-09-14 1994-02-22 The Regents Of The University Of California Solid phase and combinatorial synthesis of benzodiazepine compounds on a solid support
US5652138A (en) * 1992-09-30 1997-07-29 The Scripps Research Institute Human neutralizing monoclonal antibodies to human immunodeficiency virus
US5559410A (en) 1992-12-17 1996-09-24 Valeo Systemes D'essuyage Device for controlling the function of an electric starting motor for a windshield wiper of a rear window of an automotive vehicle and for supplying an electric motor particularly to activate the windshield
US5576220A (en) 1993-02-19 1996-11-19 Arris Pharmaceutical Corporation Thin film HPMP matrix systems and methods for constructing and displaying ligands
SG49008A1 (en) 1993-03-05 1998-05-18 Cytel Corp Hla-a2.1 binding peptides and their uses
CN1127527A (zh) 1993-05-17 1996-07-24 加利福尼亚大学董事会 人免疫缺陷型病毒感染和艾滋病的核酶基因治疗方法
US5837501A (en) 1993-07-09 1998-11-17 Akzo Nobel N.V. Nucleic acid quantitation by co-amplification of target with multiple internal controls
US5679647A (en) 1993-08-26 1997-10-21 The Regents Of The University Of California Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides
US5804566A (en) 1993-08-26 1998-09-08 The Regents Of The University Of California Methods and devices for immunizing a host through administration of naked polynucleotides with encode allergenic peptides
DK0735893T3 (da) 1993-09-14 2009-03-09 Pharmexa Inc PAN DR-bindende peptider til styrkelse af immunsvaret
US5681697A (en) 1993-12-08 1997-10-28 Chiron Corporation Solution phase nucleic acid sandwich assays having reduced background noise and kits therefor
CH686982A5 (fr) 1993-12-16 1996-08-15 Maurice Stroun Méthode pour le diagnostic de cancers.
US5519134A (en) 1994-01-11 1996-05-21 Isis Pharmaceuticals, Inc. Pyrrolidine-containing monomers and oligomers
US5593853A (en) 1994-02-09 1997-01-14 Martek Corporation Generation and screening of synthetic drug libraries
US5539083A (en) 1994-02-23 1996-07-23 Isis Pharmaceuticals, Inc. Peptide nucleic acid combinatorial libraries and improved methods of synthesis
US5739118A (en) 1994-04-01 1998-04-14 Apollon, Inc. Compositions and methods for delivery of genetic material
US7625697B2 (en) * 1994-06-17 2009-12-01 The Board Of Trustees Of The Leland Stanford Junior University Methods for constructing subarrays and subarrays made thereby
US5525735A (en) 1994-06-22 1996-06-11 Affymax Technologies Nv Methods for synthesizing diverse collections of pyrrolidine compounds
US5549974A (en) 1994-06-23 1996-08-27 Affymax Technologies Nv Methods for the solid phase synthesis of thiazolidinones, metathiazanones, and derivatives thereof
JP4064452B2 (ja) 1994-07-20 2008-03-19 ザ ジェネラル ホスピタル コーポレーション 蛋白質相互作用を検出するための相互作用補足系
US5580731A (en) 1994-08-25 1996-12-03 Chiron Corporation N-4 modified pyrimidine deoxynucleotides and oligonucleotide probes synthesized therewith
US5597909A (en) 1994-08-25 1997-01-28 Chiron Corporation Polynucleotide reagents containing modified deoxyribose moieties, and associated methods of synthesis and use
US5681702A (en) 1994-08-30 1997-10-28 Chiron Corporation Reduction of nonspecific hybridization by using novel base-pairing schemes
US5919652A (en) 1994-11-09 1999-07-06 The Regents Of The University Of California Nucleic acid molecules comprising the prostate specific antigen (PSA) promoter and uses thereof
US5736524A (en) 1994-11-14 1998-04-07 Merck & Co.,. Inc. Polynucleotide tuberculosis vaccine
US5614372A (en) * 1995-02-24 1997-03-25 Lilja; Hans Early detection of prostate cancer (CAP) by employing prostate specific antigen (PSA) and human glandular kallikrein (hGK-1)
US5962428A (en) 1995-03-30 1999-10-05 Apollon, Inc. Compositions and methods for delivery of genetic material
DE69636866D1 (en) 1995-04-11 2007-03-15 Gen Hospital Corp Reverse "two-hybrid"-systeme
EP0873415B1 (en) 1995-04-14 2008-09-10 University Of Alabama Research Foundation Fusion protein delivery system and uses thereof
WO1996032959A1 (en) 1995-04-19 1996-10-24 Acorda Therapeutics Cns neurite outgrowth modulators, and compositions, cells and methods embodying and using same
US6576607B1 (en) * 1995-04-19 2003-06-10 Acorda Therapeutics Methods using CNS neurite outgrowth modulators
US5922687A (en) 1995-05-04 1999-07-13 Board Of Trustees Of The Leland Stanford Junior University Intracellular delivery of nucleic acids using pressure
US5759776A (en) * 1995-06-05 1998-06-02 California Pacific Medical Center Targets for breast cancer diagnosis and treatment
US5861160A (en) * 1995-06-07 1999-01-19 Ambico, Inc. Isospora suis sporozoite antigen
US5585639A (en) 1995-07-27 1996-12-17 Hewlett-Packard Company Optical scanning apparatus
US5569588A (en) 1995-08-09 1996-10-29 The Regents Of The University Of California Methods for drug screening
US6248555B1 (en) * 1995-08-31 2001-06-19 The General Hospital Corporation Genetic alterations related to familial alzheimer's disease
KR19990077146A (ko) 1996-01-11 1999-10-25 길리스 스티브 유방암의 치료 및 진단용 조성물 및 방법
US7241876B2 (en) * 1996-01-11 2007-07-10 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
US20030125536A1 (en) 1996-01-11 2003-07-03 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
US20020068285A1 (en) 1996-01-11 2002-06-06 Frudakis Tony N. Compositions and methods for the therapy and diagnosis of breast cancer
US6344550B1 (en) * 1996-01-11 2002-02-05 Corixa Corporation Compositions and methods for the treatment and diagnosis of breast cancer
CU22559A1 (es) 1996-01-17 1999-05-03 Ct Ingenieria Genetica Biotech Sistema de expresión de antígenos heterologos en e. coli como proteínas de fusión
US5840839A (en) * 1996-02-09 1998-11-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Alternative open reading frame DNA of a normal gene and a novel human cancer antigen encoded therein
JP2001504799A (ja) 1996-03-11 2001-04-10 エピミューン インコーポレイテッド Ｈｌａ分子への結合アフィニティーが増加したペプチド
WO1997041255A1 (en) 1996-04-26 1997-11-06 Massachusetts Institute Of Technology Three-hybrid screening assay
EP0960204A4 (en) 1996-07-26 2002-01-23 Sloan Kettering Inst Cancer METHODS AND REAGENTS FOR GENETIC IMMUNIZATION
US5925523A (en) 1996-08-23 1999-07-20 President & Fellows Of Harvard College Intraction trap assay, reagents and uses thereof
US6183988B1 (en) * 1996-10-02 2001-02-06 The General Hospital Corporation Leukocyte-specific protein and gene, and methods of use thereof
US6365797B1 (en) 1997-10-15 2002-04-02 The Regents Of The University Of California Mice models of human prostate cancer progression
AU4818997A (en) 1996-10-15 1998-05-11 Regents Of The University Of California, The Animal models of human prostate cancer progression
US5846722A (en) 1996-10-16 1998-12-08 Terrapin Technologies, Inc. System to detect small molecule/peptide interaction
US5840501A (en) 1996-10-25 1998-11-24 Bayer Corporation Determination of cPSA
WO1998024893A2 (en) 1996-12-03 1998-06-11 Abgenix, Inc. TRANSGENIC MAMMALS HAVING HUMAN IG LOCI INCLUDING PLURAL VH AND Vλ REGIONS AND ANTIBODIES PRODUCED THEREFROM
US6800746B2 (en) * 1997-02-25 2004-10-05 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US20030185830A1 (en) * 1997-02-25 2003-10-02 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US7033827B2 (en) * 1997-02-25 2006-04-25 Corixa Corporation Prostate-specific polynucleotide compositions
WO1999019339A1 (en) 1997-10-09 1999-04-22 Human Genome Sciences, Inc. 53 human secreted proteins
US7026447B2 (en) 1997-10-09 2006-04-11 Human Genome Sciences, Inc. 53 human secreted proteins
ZA982968B (en) 1997-04-09 1998-10-27 Corixa Corp Compositions and methods for the treatment and diagnosis of breast cancer
WO1998045436A2 (en) 1997-04-10 1998-10-15 Genetics Institute, Inc. SECRETED EXPRESSED SEQUENCE TAGS (sESTs)
WO1998045435A2 (en) 1997-04-10 1998-10-15 Genetics Institute, Inc. SECRETED EXPRESSED SEQUENCE TAGS (sESTs)
ATE225670T1 (de) * 1997-04-11 2002-10-15 Searle & Co Antagonistische anti-avb3 integrin antikörper
CA2296287A1 (en) 1997-08-01 1999-02-11 Genset 5' ests for secreted proteins expressed in prostate
JP2002508182A (ja) 1997-12-17 2002-03-19 ジェンセット 分泌タンパク質の伸長ｃＤＮＡ
US20030215803A1 (en) 2000-12-07 2003-11-20 Garcia Pablo Dominguez Human genes and gene expression products isolated from human prostate
EP1053319A2 (en) 1998-01-28 2000-11-22 Chiron Corporation Human genes and gene expression products ii
ID27813A (id) * 1998-01-28 2001-04-26 Corixa Corp Senyawa-senyawa untuk terapi dan diagnosa kanker paru-paru dan metoda untuk penggunaannya
US6500938B1 (en) * 1998-01-30 2002-12-31 Incyte Genomics, Inc. Composition for the detection of signaling pathway gene expression
DK1071710T4 (da) * 1998-04-15 2011-12-12 Merck Serono Biodevelopment Genomisk sekvens for 5-lipoxygenase-aktiveringsproteinet (FLAP), polymorfe markører deri og fremgangsmåder til påvisning af astma
US6476212B1 (en) * 1998-05-26 2002-11-05 Incyte Genomics, Inc. Polynucleotides and polypeptides derived from corn ear
US20030118599A1 (en) 1999-04-02 2003-06-26 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
TW200532020A (en) 1998-07-14 2005-10-01 Corixa Corp Compositions and methods for therapy and diagnosis of prostate cancer
JP2003530816A (ja) 1998-09-28 2003-10-21 カイロン コーポレイション ヒト遺伝子および遺伝子発現産物
US6264949B1 (en) * 1998-09-29 2001-07-24 Mount Sinai School Of Medicine Of New York University Noninvasive agents for diagnosis and prognosis of the progression of fibrosis
AU1208200A (en) 1998-10-15 2000-05-01 Genetics Institute Inc. Secreted expressed sequence tags (sests)
US20020137160A1 (en) * 1998-12-17 2002-09-26 Byatt John C Nucleic acid and other molecules associated with lactation and muscle and fat deposition
CA2296792A1 (en) 1999-02-26 2000-08-26 Genset S.A. Expressed sequence tags and encoded human proteins
WO2002092787A2 (en) 2001-03-27 2002-11-21 Human Genome Sciences, Inc. Human secreted proteins
WO2000058357A1 (en) 1999-03-26 2000-10-05 Human Genome Sciences, Inc. 50 human secreted proteins
WO2000058473A2 (en) 1999-03-31 2000-10-05 Curagen Corporation Nucleic acids including open reading frames encoding polypeptides; 'orfx'
EP1187915A2 (en) 1999-04-02 2002-03-20 Corixa Corporation Compounds for therapy and diagnosis of lung cancer and methods for their use
AU774824B2 (en) 1999-04-09 2004-07-08 Corixa Corporation Compositions and methods for the treatment and diagnosis of breast cancer
WO2000073509A2 (en) 1999-06-01 2000-12-07 Incyte Genomics, Inc. Molecules for diagnostics and therapeutics
US6114123A (en) * 1999-06-14 2000-09-05 Incyte Pharmaceuticals, Inc. Lipocalin family protein
US7160694B2 (en) * 1999-06-14 2007-01-09 Millennium Pharmaceuticals, Inc. Nucleic acids encoding TANGO405 and functional fragments and uses thereof
EP1396543A3 (en) 1999-07-08 2004-03-31 Research Association for Biotechnology Primers for synthesizing full length cDNA clones and their use
EP1074617A3 (en) * 1999-07-29 2004-04-21 Research Association for Biotechnology Primers for synthesising full-length cDNA and their use
JP2002191363A (ja) * 1999-07-29 2002-07-09 Herikkusu Kenkyusho:Kk 全長ｃＤＮＡ合成用プライマー、およびその用途
WO2001018176A1 (en) * 1999-09-03 2001-03-15 Human Genome Sciences, Inc. Immunoglobulin superfamily polynucleotides, polypeptides, and antibodies
AU6063900A (en) * 1999-09-10 2001-04-10 Millennium Pharmaceuticals, Inc. Novel genes encoding proteins having prognostic, diagnostic, preventive, therapeutic, and other uses
WO2001025272A2 (en) 1999-10-04 2001-04-12 Corixa Corporation Compositions and methods for therapy and diagnosis of prostate cancer
US6893818B1 (en) * 1999-10-28 2005-05-17 Agensys, Inc. Gene upregulated in cancers of the prostate
WO2001034802A2 (en) 1999-11-12 2001-05-17 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
EP1285088A2 (en) 2000-01-13 2003-02-26 Genset Biallelic markers derived from genomic regions carrying genes involved in central nervous system disorders
WO2001051628A2 (en) 2000-01-14 2001-07-19 Millennium Pharmaceuticals, Inc. Genes compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
CZ20022756A3 (cs) 2000-01-14 2003-02-12 Corixa Corporation Prostředky a způsoby pro léčení a diagnostiku rakoviny prostaty
US20020132767A1 (en) * 2000-01-31 2002-09-19 Rosen Craig A. Nucleic acids, proteins, and antibodies
WO2001055326A2 (en) 2000-01-31 2001-08-02 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
US20030139327A9 (en) * 2000-01-31 2003-07-24 Rosen Craig A. Nucleic acids, proteins, and antibodies
CA2392398A1 (en) 2000-01-31 2001-08-02 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
WO2001059063A2 (en) 2000-01-31 2001-08-16 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
US20030013649A1 (en) * 2000-01-31 2003-01-16 Rosen Craig A. Nucleic acids, proteins, and antibodies
AU2001243142A1 (en) 2000-02-03 2001-08-14 Hyseq, Inc. Novel nucleic acids and polypeptides
WO2001057251A2 (en) 2000-02-04 2001-08-09 Aeomica, Inc. Methods and apparatus for predicting, confirming, and displaying functional information derived from genomic sequence
US20030170246A1 (en) 2000-02-11 2003-09-11 Corixa Corporation Lipophilin complexes for use in cancer diagnosis and therapy
AU2001241541A1 (en) * 2000-02-17 2001-08-27 Millennium Predictive Medicine, Inc. Novel genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of human prostate cancer
WO2001064834A2 (en) 2000-02-28 2001-09-07 Hyseq, Inc. Novel nucleic acids and polypeptides
JP2001245671A (ja) 2000-03-07 2001-09-11 Chiba Prefecture ヒト神経芽細胞腫においてクローニングされた新規遺伝子及び新規遺伝子の断片
WO2001066753A2 (en) 2000-03-09 2001-09-13 Chiron Corporation Human genes and gene expression products
AU4592601A (en) 2000-03-21 2001-10-03 Millennium Predictive Medicine Novel genes, compositions, kits, and method for identification, assessment, prevention, and therapy of ovarian cancer
JP2004504808A (ja) 2000-03-27 2004-02-19 コリクサ　コーポレイション 前立腺癌の治療及び診断のための組成物及び方法
AU2001261007A1 (en) 2000-03-29 2001-10-08 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US6436703B1 (en) * 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
WO2001075171A2 (en) 2000-04-03 2001-10-11 Corixa Corporation Methods, compositions and kits for the detection and monitoring of breast cancer
US20020192763A1 (en) * 2000-04-17 2002-12-19 Jiangchun Xu Compositions and methods for the therapy and diagnosis of prostate cancer
US6682888B1 (en) * 2000-05-05 2004-01-27 Incyte Corporation Genes expressed in alzheimer's disease
WO2001085791A1 (en) 2000-05-11 2001-11-15 Lifespan Biosciences, Inc. Nucleic acid sequences for novel gpcrs
AU2001263006A1 (en) * 2000-05-18 2001-11-26 Hyseq, Inc. Novel nucleic acids and polypeptides
WO2001092581A2 (en) 2000-05-26 2001-12-06 Corixa Corporation Compositions and methods for the therapy and diagnosis of ovarian cancer
US20020082206A1 (en) * 2000-05-30 2002-06-27 Leach Martin D. Novel polynucleotides from atherogenic cells and polypeptides encoded thereby
JP2004509612A (ja) 2000-06-05 2004-04-02 アバロン　ファーマシューティカルズ ガン遺伝子決定および特徴的な遺伝子群を用いた治療用スクリーニング
GB0014185D0 (en) * 2000-06-09 2000-08-02 Novartis Res Found Compound and method
US6974667B2 (en) 2000-06-14 2005-12-13 Gene Logic, Inc. Gene expression profiles in liver cancer
WO2001098351A2 (en) 2000-06-16 2001-12-27 Incyte Genomics, Inc. G-protein coupled receptors
US20040072996A1 (en) * 2001-06-15 2004-04-15 Lal Preeti G G-protein coupled receptors
AU2002210791A1 (en) 2000-07-28 2002-02-13 Compugen Inc. Oligonucleotide library for detecting rna transcripts and splice variants that populate a transcriptome
AU1218802A (en) 2000-09-01 2002-03-13 Epigenomics Ag Method for determining the degree of methylation of defined cytosines in genomicdna in the sequence context 5'-cpg-3'
CN1345964A (zh) 2000-09-29 2002-04-24 上海博德基因开发有限公司 一种新的多肽——己糖激酶10.01和编码这种多肽的多核苷酸
JP2004528810A (ja) 2000-10-02 2004-09-24 バイエル コーポレーション 癌組織でディファレンシャルに発現される核酸配列
US20030134283A1 (en) * 2000-10-03 2003-07-17 Peterson David P. Genes regulated in dendritic cell differentiation
WO2002028902A2 (en) * 2000-10-05 2002-04-11 Immunex Corporation Nectin polypeptides, polynucleotides, methods of making and use thereof
AU2002215345A1 (en) * 2000-10-13 2002-04-22 Eos Biotechnology, Inc. Methods of diagnosis of prostate cancer, compositions and methods of screening for modulators of prostate cancer
US20070014801A1 (en) * 2001-01-24 2007-01-18 Gish Kurt C Methods of diagnosis of prostate cancer, compositions and methods of screening for modulators of prostate cancer
EP1379651A2 (en) 2000-12-07 2004-01-14 Chiron Corporation Human genes and gene expression products isolated from human prostate
WO2002050105A1 (en) 2000-12-19 2002-06-27 Smithkline Beecham Corporation Novel compounds
US20040072264A1 (en) 2000-12-22 2004-04-15 Morris David W. Novel compositions and methods for cancer
US7820447B2 (en) 2000-12-22 2010-10-26 Sagres Discovery Inc. Compositions and methods for cancer
CN1363678A (zh) 2001-01-05 2002-08-14 上海博德基因开发有限公司 一种新的多肽——信号肽酶9.79和编码这种多肽的多核苷酸
AU2002245317A1 (en) * 2001-01-24 2002-08-06 Protein Design Labs Methods of diagnosis of breast cancer, compositions and methods of screening for modulators of breast cancer
US20040029114A1 (en) * 2001-01-24 2004-02-12 Eos Technology, Inc. Methods of diagnosis of breast cancer, compositions and methods of screening for modulators of breast cancer
WO2002059271A2 (en) 2001-01-25 2002-08-01 Gene Logic, Inc. Gene expression profiles in breast tissue
AU2002251841A1 (en) 2001-01-30 2002-08-12 Corixa Corporation Compositions and methods for the therapy and diagnosis of pancreatic cancer
DE20103510U1 (de) 2001-02-28 2001-06-07 Lion Bioscience Ag Genbibliothek
WO2003008583A2 (en) 2001-03-02 2003-01-30 Sagres Discovery Novel compositions and methods for cancer
US20040053250A1 (en) * 2001-03-05 2004-03-18 Tang Y. Tom Novel arginine-rich protein-like nucleic acids and polypeptides
US6783969B1 (en) * 2001-03-05 2004-08-31 Nuvelo, Inc. Cathepsin V-like polypeptides
US20030087250A1 (en) * 2001-03-14 2003-05-08 Millennium Pharmaceuticals, Inc. Nucleic acid molecules and proteins for the identification, assessment, prevention, and therapy of ovarian cancer
US7271240B2 (en) * 2001-03-14 2007-09-18 Agensys, Inc. 125P5C8: a tissue specific protein highly expressed in various cancers
CA2447183A1 (en) 2001-03-28 2002-10-10 Incyte Genomics, Inc. Molecules for disease detection and treatment
CA2447212A1 (en) 2001-03-29 2002-10-24 Incyte Genomics, Inc. Secretory molecules
WO2002078516A2 (en) 2001-03-30 2002-10-10 Corixa Corporation Compositions and methods for the therapy and diagnosis of cancer
WO2002079448A2 (en) 2001-03-30 2002-10-10 Incyte Genomics, Inc. G-protein coupled receptors
WO2002080852A2 (en) 2001-04-04 2002-10-17 Digital Gene Technologies, Inc. Genes expressed in intestinal epithelium and peyer's patch m cells
AU2002307466A1 (en) 2001-04-20 2002-11-05 Millennium Pharmaceutical, Inc. Method for detecting breast cancer cells
US20030083263A1 (en) * 2001-04-30 2003-05-01 Svetlana Doronina Pentapeptide compounds and uses related thereto
US6794501B2 (en) * 2001-05-04 2004-09-21 Ludwig Institute For Cancer Research Colon cancer antigen panel
EP1515982A4 (en) 2001-05-09 2005-10-26 Corixa Corp METHODS AND COMPOSITIONS FOR THE THERAPY AND DIAGNOSIS OF PROSTATE CANCER
WO2002092001A2 (en) 2001-05-11 2002-11-21 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US7171311B2 (en) 2001-06-18 2007-01-30 Rosetta Inpharmatics Llc Methods of assigning treatment to breast cancer patients
US7189507B2 (en) * 2001-06-18 2007-03-13 Pdl Biopharma, Inc. Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer
US20040076955A1 (en) * 2001-07-03 2004-04-22 Eos Biotechnology, Inc. Methods of diagnosis of bladder cancer, compositions and methods of screening for modulators of bladder cancer
AU2002364890A1 (en) 2001-07-09 2003-06-30 Incyte Genomics, Inc. Molecules for disease detection and treatment
US20050118582A1 (en) 2001-07-12 2005-06-02 Anita Swarnakar Nucleic acid-associated proteins
US20030099974A1 (en) * 2001-07-18 2003-05-29 Millennium Pharmaceuticals, Inc. Novel genes, compositions, kits and methods for identification, assessment, prevention, and therapy of breast cancer
WO2003009814A2 (en) 2001-07-25 2003-02-06 Millennium Pharmaceuticals, Inc. Novel genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of prostate cancer
CA2456955A1 (en) 2001-08-09 2003-10-02 Nuvelo, Inc. Novel nucleic acids and secreted polypeptides
WO2003016475A2 (en) 2001-08-14 2003-02-27 The General Hospital Corporation Nucleic acid and amino acid sequences involved in pain
US20030096751A1 (en) * 2001-08-20 2003-05-22 Ramanathan Chandra S. G-protein coupled receptor polynucleotides and methods of use thereof
EP1293569A3 (en) 2001-09-14 2004-03-31 Research Association for Biotechnology Full-length cDNAs
JP2003088388A (ja) * 2001-09-14 2003-03-25 Herikkusu Kenkyusho:Kk 新規な全長ｃＤＮＡ
KR101008758B1 (ko) * 2001-09-18 2011-01-14 제넨테크, 인크. 종양의 진단 및 치료를 위한 방법 및 이를 위한 조성물
CN1412309A (zh) 2001-10-08 2003-04-23 中国人民解放军军事医学科学院放射医学研究所 人支气管上皮细胞恶性转化差异表达基因的cDNA文库及与肺癌病变相关的克隆
MXPA04004072A (es) 2001-10-30 2004-09-06 Johnson & Johnson Metodos para valorar y tratar leucemia.
US20070072178A1 (en) 2001-11-05 2007-03-29 Torsten Haferlach Novel genetic markers for leukemias
IL161268A0 (en) * 2001-11-07 2004-09-27 Agensys Inc Nucleic acid and corresponding protein entitled 161p2f10b and pharmaceutical and diagnostic compositions containing the same
US20030232350A1 (en) * 2001-11-13 2003-12-18 Eos Biotechnology, Inc. Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer
US20040115629A1 (en) * 2002-01-09 2004-06-17 Panzer Scott R Molecules for diagnostics and therapeutics
AU2003210518A1 (en) 2002-01-16 2003-09-02 Incyte Genomics, Inc. Molecules for diagnostics and therapeutics
WO2003068268A2 (en) 2002-02-14 2003-08-21 Bioinvent International Ab Treatment, diagnosis and imaging of disease
WO2003083047A2 (en) 2002-03-01 2003-10-09 Exelixis, Inc. MP53s AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE
AU2003217992A1 (en) 2002-03-06 2003-09-22 Incyte Corporation Nucleic acid-associated proteins
JP2003259877A (ja) 2002-03-11 2003-09-16 Sumitomo Pharmaceut Co Ltd 肝線維症疾患マーカーおよびその利用
AU2003222103A1 (en) 2002-03-28 2003-10-13 Idec Pharmaceuticals Corporation Novel gene targets and ligands that bind thereto for treatment and diagnosis of colon carcinomas
US20030194704A1 (en) 2002-04-03 2003-10-16 Penn Sharron Gaynor Human genome-derived single exon nucleic acid probes useful for gene expression analysis two
WO2003087768A2 (en) 2002-04-12 2003-10-23 Mitokor Targets for therapeutic intervention identified in the mitochondrial proteome
EP1545613B9 (en) * 2002-07-31 2012-01-25 Seattle Genetics, Inc. Auristatin conjugates and their use for treating cancer, an autoimmune disease or an infectious disease
JP2004121218A (ja) 2002-08-06 2004-04-22 Jenokkusu Soyaku Kenkyusho:Kk 気管支喘息または慢性閉塞性肺疾患の検査方法
WO2004015108A1 (en) * 2002-08-09 2004-02-19 Melbourne Health Mammalian grainyhead transcription factors
WO2004016733A2 (en) 2002-08-16 2004-02-26 Agensys, Inc. Nucleic acid and corresponding protein entitled 251p5g2 useful in treatment and detection of cancer
CN1477123A (zh) 2002-08-23 2004-02-25 上海博德基因开发有限公司 一种多肽——转录因子43和编码这种多肽的多核苷酸
WO2004023973A2 (en) * 2002-09-12 2004-03-25 Incyte Corporation Molecules for diagnostics and therapeutics
AU2003279084A1 (en) 2002-09-25 2004-04-19 Genentech, Inc. Novel compositions and methods for the treatment of psoriasis
EP1560597A4 (en) 2002-10-29 2007-06-27 Pharmacia Corp DIFFERENTIALLY EXPRESSED GENES INVOLVED IN CANCER, POLYPEPTIDES CODED THEREWITH, AND METHODS OF USING GENES
US20080213166A1 (en) 2002-11-20 2008-09-04 Biogen Idec Inc. Novel Gene Targets and Ligands that Bind Thereto for Treatment and Diagnosis of Colon Carcinomas
AU2003294510A1 (en) 2002-11-22 2004-06-18 Incyte Corporation Transporters and ion channels
US20040253606A1 (en) 2002-11-26 2004-12-16 Protein Design Labs, Inc. Methods of detecting soft tissue sarcoma, compositions and methods of screening for soft tissue sarcoma modulators
WO2004066948A2 (en) 2003-01-29 2004-08-12 Exelixis Inc. Mapcaxs as modifiers of the apc and axin pathways and methods of use
EP1447413A3 (en) 2003-02-14 2006-01-04 Research Association for Biotechnology Full-length human cDNA
US20050164324A1 (en) * 2003-06-04 2005-07-28 Gygi Steven P. Systems, methods and kits for characterizing phosphoproteomes
SG195524A1 (en) * 2003-11-06 2013-12-30 Seattle Genetics Inc Monomethylvaline compounds capable of conjugation to ligands
EP2078732B1 (en) * 2006-07-10 2015-09-16 Fujita Health University Method of identifying a candidate diagnostic or therapeutic antibody using flow cytometry
JO3421B1 (ar) 2011-06-20 2019-10-20 H Lundbeck As طريقة لإعطاء 1-((1ار.3س)-6-كلورو-3-فينيل-اندان-1-ايل)-1.2.2-ترايميثيل- بيبيرازين واملاجها لمعالجة انفصام الشخصية
CN104010774B (zh) 2011-09-15 2017-10-13 康富真信息技术股份有限公司 用于自动生成机器人程序的系统和方法

Also Published As

Publication number Publication date
ES2391892T3 (es) 2012-11-30
EP1576132A4 (en) 2007-09-05
IL200404A0 (en) 2010-04-29
EP1576104A2 (en) 2005-09-21
EP1576170B1 (en) 2012-08-15
WO2004016762A2 (en) 2004-02-26
US7115727B2 (en) 2006-10-03
AU2003243151A8 (en) 2004-03-03
EP1576132A2 (en) 2005-09-21
US8426571B2 (en) 2013-04-23
US7250498B2 (en) 2007-07-31
US20070298424A1 (en) 2007-12-27
US8057996B2 (en) 2011-11-15
WO2004016736A3 (en) 2006-10-05
JP2009278977A (ja) 2009-12-03
AU2003243151A1 (en) 2004-03-03
AU2003236553B2 (en) 2007-09-20
US20130177569A1 (en) 2013-07-11
US20110201052A1 (en) 2011-08-18
IL166532A0 (en) 2006-01-15
AU2003228717B2 (en) 2008-02-21
US7612172B2 (en) 2009-11-03
EP1576104A4 (en) 2007-10-10
ES2392341T3 (es) 2012-12-07
WO2004016734A3 (en) 2006-08-24
AU2003232116A1 (en) 2004-03-03
WO2004016734A2 (en) 2004-02-26
EP2332966A1 (en) 2011-06-15
EP1576130A2 (en) 2005-09-21
US20080181885A1 (en) 2008-07-31
SI1576132T1 (sl) 2012-12-31
US20040192597A1 (en) 2004-09-30
CA3066279A1 (en) 2004-02-26
US20040083497A1 (en) 2004-04-29
JP2009278988A (ja) 2009-12-03
JP2009159963A (ja) 2009-07-23
CA2493921C (en) 2015-12-08
CA2493923A1 (en) 2004-02-26
IL200404A (en) 2014-07-31
US20090252747A1 (en) 2009-10-08
IL166532A (en) 2011-09-27
SI1576170T1 (sl) 2012-12-31
US20070059729A1 (en) 2007-03-15
EP1576132B1 (en) 2012-08-15
AU2003228717A1 (en) 2004-03-03
AU2008207531A1 (en) 2008-09-18
US20130267024A1 (en) 2013-10-10
CA2493925A1 (en) 2004-02-26
WO2004016736A2 (en) 2004-02-26
IL166655A0 (en) 2006-01-15
EP2301954A2 (en) 2011-03-30
US20040053348A1 (en) 2004-03-18
EP1576130A4 (en) 2007-08-08
AU2003236553C1 (en) 2008-05-01
EP2301954A3 (en) 2012-05-09
JP2006513724A (ja) 2006-04-27
US8604169B2 (en) 2013-12-10
IL166564A0 (en) 2006-01-15
IL233223A (en) 2015-03-31
AU2003232116B2 (en) 2008-05-29
EP1576170A4 (en) 2008-07-23
IL166531A (en) 2014-07-31
JP4490502B2 (ja) 2010-06-30
IL233223A0 (en) 2014-07-31
US7696336B2 (en) 2010-04-13
CA2493921A1 (en) 2004-02-26
AU2003236553A1 (en) 2004-03-03
US20100297006A1 (en) 2010-11-25
US20110195019A1 (en) 2011-08-11
US20040081653A1 (en) 2004-04-29
JP2010142228A (ja) 2010-07-01
JP2006511232A (ja) 2006-04-06
US20040213778A1 (en) 2004-10-28
WO2004016733A2 (en) 2004-02-26
CA2493923C (en) 2020-02-18
CA2493928C (en) 2014-04-01
WO2004016799A2 (en) 2004-02-26
AU2003258269A1 (en) 2004-03-03
IL166531A0 (en) 2006-01-15
IL166564A (en) 2012-01-31
US20070231261A1 (en) 2007-10-04
WO2004016733A3 (en) 2006-03-16
US20100297669A1 (en) 2010-11-25
PT1576170E (pt) 2012-11-05
DK1576132T3 (da) 2012-10-01
CA2493928A1 (en) 2004-02-26
EP1576170A2 (en) 2005-09-21
IL166655A (en) 2010-06-16
AU2003258269C1 (en) 2004-03-03
WO2004016799A3 (en) 2007-04-05
DK1576170T3 (da) 2012-11-26
PT1576132E (pt) 2012-10-31
WO2004016762A3 (en) 2007-01-18
AU2003258269B2 (en) 2007-06-28

Similar Documents

Publication Publication Date Title
CY1113247T1 (el) Νουκλεϊνικα οξεα με τιτλο 273ρ4β7 και η χρηση τους στην ανιχνευση καρκινου
CY1113044T1 (el) Παραλλαγματα αντιγονου αρχεγονων κυτταρων προστατη (psca) και υποαλληλουχιες εξ αυτων
CY1114855T1 (el) Αντισωματα και μορια που προερχονται απο αυτα που δεσμευονται στις πρωτεϊνες toy steap-1
CY1114069T1 (el) Νουκλεϊνικο οξυ και αντιστοιχη πρωτεϊνη με τιτλο 161p2f10b χρησιμα στη θεραπεια και ανιχνευση καρκινου
CY1123400T1 (el) Ανθρωπινα anti-il-23 αντισωματα, συνθεσεις, μεθοδοι και χρησεις
WO2004000094A3 (en) Predictive markers in cancer therapy
CY1113064T1 (el) Νουκλεϊνικο οξυ και αντιστοιχη πρωτεϊνη με τιτλο 184ρ1ε2 χρησιμα στη θεραπεια και ανιχνευση καρκινου
CY1110256T1 (el) Διαμεμβρανικο αντιγονο λεκτινης τυπου c εκφραζομενο σε καρκινο στον προστατη ανθρωπου και χρησεις αυτου
ES2177964T3 (es) Procedimiento de produccion de celulas t activadas marcadas especificas de tumores y su uso para el tratamiento de tumores.
CY1108765T1 (el) ΑΓΩΓΗ ME ΑΝΤΙΣΩΜΑΤΑ ANTI-ErbB2
TR200103560T2 (tr) Göğüs kanserinin teşhis ve tedavisi için bileşimler ve bunların kullanımı
TR200002731T2 (tr) Proteolitik antikorların indüktör ve inhibitörlerinin tanımlanması, kompozisyonları ve kullanımları için metotlar
CY1105439T1 (el) Κυτταρα, μεθοδοι καλλιεργειας και η χρηση τους στη θepαπεια με αυτολογη μεταμοσχευση
EA200100264A1 (ru) Ангиоцидин: адгезионный рецептор опухолей клетки, специфический для cys-ser-val-thr-cys-gly
ATE286745T1 (de) Verwendung von antikörpern zur vakzinierung gegen krebs
DK1173766T3 (da) Isoform af tenascin-C som markör for neoplasier
EP1778284A4 (en) NUCLEIC ACIDS AND RELATED 58P1D12 PROTEINS FOR THE TREATMENT AND DETECTION OF CANCER
CY1112424T1 (el) Πυρηνικο οξυ και αντιστοιχη πρωτεϊνη με τιτλο 238ρ1β2 χρησιμα στην αγωγη και ανιχνευση του καρκινου
CY1113332T1 (el) Νουκλεϊκα οξεα και αντιστοιχες πρωτεϊνες με ονομασια 191p4d12(b) χρησιμα στην αγωγη και ανιχνευση καρκινου
CY1116795T1 (el) Αντισωματα και σχετικα μορια που δεσμευονται στις πρωτεϊνες toy psca
CY1108768T1 (el) Νουκλεϊνικο οξυ και αντιστοιχη πρωτεϊνη ονομαζομενη 121ρ2α3 χρησιμη για την αγωγη και την ανιχνευση του καρκινου
MXPA05002520A (es) Secuencia de acido nucleico 98p4b6 asociada con el cancer.
CY1113516T1 (el) Νουκλεϊκο οξυ και αντιστοιχη πρωτεϊνη με ονομασια 158p1d7 χρησιμα στην αγωγη και ανιχνευση καρκινου ουροδοχου κυστης και αλλων καρκινων
CY1114674T1 (el) Αντισωματα και σχετικα μορια που προσδενονται σε 24p4c12 πρωτεϊνες
WO2001051516A3 (de) Fusionsproteine zur stimulierung von cytotoxischen t-zellen